ALZHEIMER’S DRUG MAY BE FATAL TO SOME ALHEIMER’S DRUG MAY BE FATAL TO

The Alzheimer’s drug Reminyl (galantamine hydrobromide) could prove fatal to patients with mild cognitive impairment (MCI), according to Ortho-McNeil Neurologics, the company that makes the drug. The warning was issued to healthcare professionals following the findings of two clinical trials.


In these studies, half the Reminyl-related deaths were due to vascular problems such as myocardial infarction or stroke, and sudden death. The drug-maker also pointed out that, compared with other studies of the drug, the death rate in placebo-treated MCI patients was notably lower than the mortality rate in placebo-treated Alzheimer patients.


Reminyl is approved in 69 countries for mild-to-moderate Alzheimer’s, but not for MCI. People with MCI have memory impairment that is greater than expected for their age and education, and is considered to be a condition separate from Alzheimer’s.

What Doctors Don't Tell You Written by What Doctors Don't Tell You

Get the Healthiest Newsletter!

Get a dose of Healthy delivered straight to your inbox. Each FREE issue features amazing content that will elevate your Body, Mind, and Spirit.

Your data is never shared with 3rd parties

Body+Mind+Spirit

TRANSFORM YOUR LIFE?

Try the Internet's Longest-Running Wellness Program.